Joint Formulary & PAD

Continuous Glucose Monitoring - Congenital hyperinsulinism

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Device
Associated Icons :
BNF SPC
ICB
Restrictions / Comments :
Important

Patients must be under the care of a national CHI centre (see narrative for details).

Documents :
 

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Continuous Glucose Monitoring
Indication :
Congenital hyperinsulinism
Group Name :
Keywords :
real time, rtCGM, gastrostomy, CGM
Brand Names Include :
Freestyle Libre 3, Dexcom One, Dexcom G6, Dexcom G7, Medtronic Guardian, Dexcom 6 & Dexcom 7
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1

Other Indications

Below are listed other indications that Continuous Glucose Monitoring is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Congenital hyperinsulinism.

  • No records returned.

Committee Recommendations (1)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves real time continuous glucose monitoring (RTCGM) devices for patients with congenital hyperinsulinism (CHI) who are under the care of one of the 3 nationally commissioned centres:

·       Great Ormond Street Hospital for Children NHS Foundation Trust

·       Manchester University NHS Foundation Trust

·       Alder Hey Children’s NHS Foundation Trust

AND who require overnight continuous enteral glucose delivery via a gastrostomy feed pump.  rtCGM acts as an additional alert in case of gastrostomy feed pump failure.

RTCGM will be given a RED traffic light status for this indication.